Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
GILD Gilead Sciences, Inc. daily Stock Chart
GILD [NASD]
Gilead Sciences, Inc.
Healthcare | Biotechnology | USA
financial highlights | statements
IndexS&P 500 P/E10.50 EPS (ttm)6.80 Insider Own0.40% Shs Outstand1.30B Perf Week0.24%
Market Cap92.99B Forward P/E11.05 EPS next Y6.47 Insider Trans-10.75% Shs Float1.29B Perf Month5.66%
Income8.96B PEG- EPS next Q1.55 Inst Own80.60% Short Float1.40% Perf Quarter-6.58%
Sales24.69B P/S3.77 EPS this Y-22.80% Inst Trans-0.14% Short Ratio2.49 Perf Half Y-4.88%
Book/sh15.75 P/B4.54 EPS next Y5.09% ROA5.30% Target Price85.77 Perf Year8.95%
Cash/sh18.44 P/C3.88 EPS next 5Y-6.25% ROE15.60% 52W Range64.02 - 89.54 Perf YTD-0.25%
Dividend2.28 P/FCF11.98 EPS past 5Y36.20% ROI19.90% 52W High-20.19% Beta1.16
Dividend %3.19% Quick Ratio2.80 Sales past 5Y21.90% Gross Margin82.10% 52W Low11.62% ATR1.33
Employees10000 Current Ratio2.80 Sales Q/Q-21.80% Oper. Margin50.70% RSI (14)55.33 Volatility2.22% 1.83%
OptionableYes Debt/Eq1.41 EPS Q/Q-43.10% Profit Margin14.00% Rel Volume0.69 Prev Close70.94
ShortableYes LT Debt/Eq1.29 EarningsJul 31 AMC Payout80.30% Avg Volume7.27M Price71.46
Recom2.10 SMA202.54% SMA501.80% SMA200-6.29% Volume5,026,797 Change0.73%
May-02-18Reiterated Maxim Group Buy $94 → $89
Mar-06-18Reiterated Barclays Overweight $90 → $95
Feb-22-18Reiterated Leerink Partners Mkt Perform $83 → $80
Feb-12-18Reiterated Mizuho Buy $83 → $95
Feb-08-18Reiterated Citigroup Buy $103 → $105
Jan-26-18Upgrade Jefferies Hold → Buy
Jan-16-18Upgrade Wells Fargo Market Perform → Outperform
Dec-20-17Downgrade Credit Suisse Outperform → Neutral
Nov-30-17Upgrade Maxim Group Hold → Buy $94
Nov-13-17Downgrade Argus Buy → Hold
Nov-08-17Reiterated Mizuho Buy $77 → $83
Oct-11-17Resumed Barclays Overweight $90
Oct-05-17Initiated Oppenheimer Perform
Oct-04-17Resumed Jefferies Hold $93
Sep-15-17Initiated RBC Capital Mkts Outperform $94
Sep-05-17Reiterated Wells Fargo Market Perform $73 → $81
Aug-31-17Upgrade Argus Hold → Buy
Aug-31-17Resumed William Blair Outperform $87
Jul-11-17Resumed Jefferies Hold
Jun-23-17Initiated Deutsche Bank Buy $79
Jun-20-18 11:30AM  2 High-Flying Biotech Stocks With Even More Room to Grow Motley Fool
09:51AM  Glaxo Venture's Lofty Goal in HIV: Eclipse Gilead as Top Player Bloomberg
08:59AM  GSK takes billion-dollar drug fight with Gilead to top AIDS meeting Reuters
Jun-19-18 06:32AM  3 Great Reasons to Buy Gilead Sciences Motley Fool
Jun-17-18 08:00AM  1 Under-the-Radar Dividend Growth Stock to Buy Right Now Motley Fool
Jun-15-18 02:31PM  Cash for NASH: 2 Top Biotech Takeover Targets and 3 Potential Buyers Motley Fool
10:37AM  Big Biotech Set for Earnings Blowout? Barrons.com
09:11AM  Zacks Value Investor Highlights: Gilead Sciences, Biogen, Celgene, Lannett and Valeant Zacks
Jun-14-18 04:23PM  Glaxo Pops But Analysts Say It's Unlikely To Swipe Gilead Share In HIV Investor's Business Daily
09:23AM  NASH Space in Focus as Galmed (GLMD) Posts Positive Data Zacks
09:01AM  GSK's two-drug HIV treatment meets main goal in late stage studies Reuters
08:30AM  Consolidated Research: 2018 Summary Expectations for Encana, Netflix, Veon, The Walt Disney, Gilead Sciences, and Cloudera Fundamental Analysis, Key Performance Indications GlobeNewswire
07:05AM  Free Technical Reports on Gilead Sciences and Three Additional Biotech Equities ACCESSWIRE
Jun-11-18 08:30AM  Gilead Sciences Chief Scientific Officer John McHutchison Appointed Officer of the Order of Australia CNBC
08:30AM  Gilead Sciences Chief Scientific Officer John McHutchison Appointed Officer of the Order of Australia Business Wire
Jun-07-18 05:36PM  Should You Stick With Gilead Sciences? Motley Fool
10:16AM  Gilead: The Turnaround Is Happening This Year Barrons.com
06:00AM  Gilead's Hot Stock May Cool Fast Investopedia
Jun-06-18 03:34PM  Gilead Collaborates with Hookipa for HBV and HIV Therapies Zacks
08:31AM  Biotech Stock Roundup: Regeneron, Celgene, Amgen Impress at ASCO Zacks
06:02AM  2 Cheap Dividend Stocks You Can Buy Right Now Motley Fool
Jun-05-18 07:01PM  New Ebola Outbreak May Open Door to Finding Drugs Bloomberg
08:20AM  Today's Research Reports on Trending Tickers: Gilead Sciences and bluebird bio ACCESSWIRE
12:21AM  After Soaring to New Highs, Crispr Therapeutics AG Stock Ripe for a Fall InvestorPlace
Jun-04-18 05:00PM  Gilead Sciences Announces Leadership Changes in Corporate Development and Strategy Business Wire
09:00AM  Kite Announces New Data Analyses for CAR T Therapy in Patients with Blood Cancers at the 2018 American Society of Clinical Oncology Meeting Business Wire
09:00AM  Kite Announces Initial Results From a Phase 1 Study of T Cell Receptor (TCR) Cell Therapy in HPV-16-Positive Solid Tumors Business Wire
Jun-03-18 11:35AM  Madrigal Pharma shares skyrocket 145% on positive results for liver disease therapy MarketWatch
09:33AM  3 Reasons Gilead Sciences Is a Better Value Stock Than Amgen Motley Fool
Jun-01-18 04:40PM  Conquering cancer in the Windy City CNBC Videos
12:49PM  Has the Gilead Sciences Buy Argument Collapsed? Motley Fool
11:08AM  Better Know Biotech: 2 Stocks You've Got to Know About Motley Fool
07:05AM  Blog Exposure - Gilead Announces Approval of Epclusa in China ACCESSWIRE
06:15AM  5 Top Stocks to Buy in June Motley Fool
May-31-18 01:42PM  ASCO Conference Preview: Here's What Biotech Investors Need to Watch Motley Fool
11:05AM  Peaking late: How Vertex became biotech's model citizen American City Business Journals
11:00AM  Is GlaxoSmithKline plc Stock a Buy? Motley Fool
10:34AM  Gilead & Galapagos Announce Positive Data on Filgotinib Zacks
10:21AM  2018 ASCO Conference Roundup Motley Fool
09:11AM  Why Is Gilead Sciences (GILD) Down 7.2% Since Its Last Earnings Report? Zacks
May-30-18 09:03PM  Read This Before You Buy Immuno-Oncology Stocks Motley Fool
04:02PM  GILEAD AND GALAPAGOS ANNOUNCE RESULTS WITH FILGOTINIB IN THE PHASE 2 EQUATOR STUDY IN PSORIATIC ARTHRITIS AND PROGRESSION INTO PHASE 3 FOR THE SELECTION STUDY IN ULCERATIVE COLITIS GlobeNewswire
04:01PM  Gilead Sciences to Present at the Goldman Sachs 39th Annual Global Healthcare Conference on Wednesday, June 13 Business Wire
04:01PM  Gilead and Galapagos Announce Results With Filgotinib in the Phase 2 Equator Study in Psoriatic Arthritis and Progression Into Phase 3 for the Selection Study in Ulcerative Colitis Business Wire
01:33PM  Trump says drugmakers are going to announce massive voluntary price cuts in two weeks CNBC
11:43AM  Biotech ETFs Are the Best Way to Play the Recovering Sector InvestorPlace
08:26AM  Biotech Stock Roundup: GILD Epclusa's China Approval, BMRN Palynziq's FDA Nod Zacks
08:14AM  Benzinga's Daily Biotech Pulse: Chinese Cheer For Gilead, Immutep Presents Positive Phase 1 Data, FDA Accepts Exelixis sNDA Benzinga
01:00AM  China Drug Administration Approves Epclusa® (Sofosbuvir/Velpatasvir), Gileads Pan-Genotypic Treatment for Chronic Hepatitis C Virus Infection Business Wire
May-29-18 10:16AM  3 Top Value Stocks to Buy Now Motley Fool
May-27-18 06:32AM  3 Healthcare Stocks That Are Undeniably Dirt Cheap Right Now Motley Fool
May-24-18 11:07AM  Will Right to Try Bill Boost Biotech ETFs? ETF Trends
May-23-18 04:01PM  Gilead Sciences to Present at the Jefferies 2018 Healthcare Conference on Wednesday, June 6 Business Wire
06:00AM  He helped Gilead score billions from HIV, hepatitis C drugs now he's building a cancer fighter American City Business Journals
May-22-18 06:31AM  3 Biotechs on the FDA's Naughty List That Should Be on Investors' Buy Lists Motley Fool
May-18-18 02:44PM  FDA Shame List: 40 Drug Makers That Try to Block Generic Drugs InvestorPlace
10:46AM  EU warns of possible birth defect link to GSK's HIV drug Reuters
May-17-18 04:48PM  The FDA Is Trying To 'Shame' Celgene, Gilead Here's Why It Won't Work Investor's Business Daily
04:13PM  Gilead, BioMarin among Bay Area drug makers shamed by FDA in generics 'gaming' list American City Business Journals
10:38AM  Sangamo Therapeutics Stock History Motley Fool
10:02AM  FDA names drugmakers likely blocking access to branded drug samples Reuters
09:15AM  3 High-Yield Stocks With Virtual Monopolies Motley Fool
May-16-18 11:10AM  Breakout Watch: Biotech Stock With 172% Growth Enters Buy Zone Investor's Business Daily
May-15-18 10:59AM  U.S. Food and Drug Administration Approves Expanded Indication for Truvada® (Emtricitabine and Tenofovir Disoproxil Fumarate) for Reducing the Risk of Acquiring HIV-1 in Adolescents Business Wire
08:30AM  Kite Announces New Worldwide Facilities and Expanded Collaboration With National Cancer Institute to Support Cell Therapy Pipeline Business Wire
May-14-18 01:43PM  Why Trumps drug-price pitch makes no sense MarketWatch
May-11-18 05:30PM  Final Trade: IBB, GILD & more CNBC Videos
04:27PM  You should know the cost of a drug or procedure before it... CNBC Videos
12:01PM  Cramer says it's 'very hard to put a price on' lifesaving drugs CNBC
May-10-18 01:00PM  Gilead May Rebound By 12% Short Term Investopedia
May-09-18 04:30PM  Harish Manwani Joins Gilead Sciences Board of Directors Business Wire
11:20AM  Why Bristol-Myers Squibb Stock Crashed in April Motley Fool
08:12AM  3 Stocks That Turned $10,000 Into $1 Million Motley Fool
May-08-18 05:15PM  What Investors Should Know About Gilead Sciences Incs (NASDAQ:GILD) Financial Strength Simply Wall St.
01:50PM  Why Sangamo Therapeutics Stock Dropped Today Motley Fool
09:00AM  Gilead Sciences to Present at the Bank of America Merrill Lynch Healthcare Conference on Wednesday, May 16 Business Wire
04:58AM  UK biotech firm Autolus joins CAR-T rush with Nasdaq IPO filing Reuters
May-07-18 07:30AM  Could Unknown Orgenesis (ORGS) Be The Next Double Or Triple In The Cell Therapy Space? ACCESSWIRE
07:20AM  The Zacks Analyst Blog Highlights: BP, Gilead, Enterprise Products and Colgate Zacks
May-04-18 11:48AM  Top Stock Reports for BP, Gilead, Enterprise Products & Colgate Zacks
08:01AM  5 Value Stocks to Book Gains Using Price-to-Book Ratio Zacks
07:00AM  Is Gilead Sciences Stock Finally a Bargain? Motley Fool
May-03-18 03:56PM  Edited Transcript of GILD earnings conference call or presentation 1-May-18 8:30pm GMT Thomson Reuters StreetEvents
01:58PM  Top 5 Biotech Stocks for 2018 Investopedia
10:23AM  Did Gilead Sciences Make a Big Mistake? Motley Fool
10:21AM  Company News for May 3, 2018 Zacks
07:47AM  Gileads latest quarter keeps Wall Street waiting on a turnaround MarketWatch
06:32AM  5 Reasons You Shouldn't Worry About Gilead Sciences' Ugly Q1 Results Motley Fool
May-02-18 04:34PM  Why Molson Coors, Gilead Sciences, and Yum China Holdings Slumped Today Motley Fool -7.83%
04:22PM  Gilead and Snap slip while Apple and AmerisourceBergen jump Associated Press
03:26PM  Is Gilead's 2018 Hepatitis C Drug Franchise Outlook In Trouble? Investor's Business Daily
10:19AM  Gilead Earnings: More Bad News for Big Biotech Barrons.com
09:33AM  The Zacks Analyst Blog Highlights: Apple, Snap, Gilead and T-Mobile U.S. Zacks
09:29AM  Stocks to Watch: Apple, T-Mobile, Mastercard, Snap, CVS, Mondelez, Xerox, Gilead, Clorox, Allstate, Coors The Wall Street Journal
09:23AM  Biotech Stock Roundup: ALXN, VRTX Post Solid Results, GILD Disappoints in Q1 Zacks
09:12AM  Gilead (GILD) Q1 Earnings & Sales Miss Estimates on Weak HCV Zacks
08:23AM  Gilead Sinks Most in Over a Year After Disappointing Earnings Bloomberg
07:41AM  Benzinga's Daily Biotech Pulse: SIGA Rallies On FDA Panel Backing, Rigel And Gilead React To Earnings Benzinga
06:01AM  Gilead Sciences' First-Quarter Twist: Weak HIV Sales Motley Fool
May-01-18 07:05PM  Gilead Sciences, Inc. Stock Declined After Earnings Miss InvestorPlace
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a PI3K delta inhibitor for certain blood cancers; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and Lexiscan, an injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging. In addition, the company offers Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B; AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, hematology/oncology, inflammation/respiratory diseases, and others. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen Sciences Ireland UC, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MARTIN JOHN CDirectorJun 01Option Exercise23.6050,0001,180,0003,067,762Jun 05 07:34 PM
MARTIN JOHN CDirectorJun 01Sale68.1350,0003,406,4953,017,762Jun 05 07:34 PM
Cogan John FrancisDirectorMay 04Option Exercise26.625,836155,32558,455May 08 01:59 PM
MILLIGAN JOHN FPresident and CEOMay 04Option Exercise27.0780,0002,165,6001,294,306May 08 06:29 PM
Cogan John FrancisDirectorMay 04Sale65.095,836379,88552,619May 08 01:59 PM
MARTIN JOHN CDirectorMay 01Option Exercise23.6050,0001,180,0003,067,762May 03 01:07 PM
MARTIN JOHN CDirectorMay 01Sale72.1950,0003,609,6603,017,762May 03 01:07 PM
Cogan John FrancisDirectorApr 27Option Exercise26.625,833155,24558,452Apr 30 05:39 PM
Cogan John FrancisDirectorApr 27Sale73.915,833431,11752,619Apr 30 05:39 PM
Cogan John FrancisDirectorApr 20Option Exercise26.625,833155,24558,452Apr 23 07:16 PM
Cogan John FrancisDirectorApr 20Sale73.745,833430,13052,619Apr 23 07:16 PM
Cogan John FrancisDirectorApr 13Option Exercise26.625,833155,24558,452Apr 16 06:45 PM
Cogan John FrancisDirectorApr 13Sale75.565,833440,74152,619Apr 16 06:45 PM
Cogan John FrancisDirectorApr 06Option Exercise26.625,833155,24558,452Apr 09 06:41 PM
Cogan John FrancisDirectorApr 06Sale74.475,833434,38452,619Apr 09 06:41 PM
Cogan John FrancisDirectorApr 02Option Exercise26.625,833155,24558,452Apr 04 04:23 PM
MARTIN JOHN CDirectorApr 02Option Exercise23.6050,0001,180,0003,067,762Apr 04 07:34 PM
MARTIN JOHN CDirectorApr 02Sale73.1450,0003,656,8063,017,762Apr 04 07:34 PM
Cogan John FrancisDirectorApr 02Sale74.935,833437,06752,619Apr 04 04:23 PM
Cogan John FrancisDirectorMar 23Option Exercise26.625,833155,24558,452Mar 26 06:48 PM
Cogan John FrancisDirectorMar 23Sale75.025,833437,58852,619Mar 26 06:48 PM
Cogan John FrancisDirectorMar 16Option Exercise26.625,833155,24558,452Mar 20 01:28 PM
Cogan John FrancisDirectorMar 16Sale80.095,833467,13852,619Mar 20 01:28 PM
Cogan John FrancisDirectorMar 12Option Exercise26.625,833155,24558,452Mar 13 04:29 PM
Cogan John FrancisDirectorMar 12Sale80.935,833472,06552,619Mar 13 04:29 PM
MARTIN JOHN CExecutive ChairmanMar 01Option Exercise23.6050,0001,180,0003,067,762Mar 05 06:54 PM
Alton Gregg HEVP,Corporate &Medical AffairsMar 01Option Exercise40.5617,250699,66069,426Mar 05 07:04 PM
MOORE NICHOLAS GDirectorMar 01Option Exercise0.00178012,233Mar 05 08:42 PM
Alton Gregg HEVP,Corporate &Medical AffairsMar 01Sale78.6925,0001,967,31544,426Mar 05 07:04 PM
MARTIN JOHN CExecutive ChairmanMar 01Sale78.6550,0003,932,3753,017,762Mar 05 06:54 PM
Washington Robin LEVP, CFOFeb 28Sale80.315,000401,566105,405Mar 02 06:47 PM
Alton Gregg HEVP,Corporate &Medical AffairsFeb 20Sale81.5414,4351,176,9920Feb 21 06:51 PM
YOUNG KEVINChief Operating OfficerFeb 10Option Exercise0.00908016,237Feb 13 04:58 PM
WILSON GAYLE EDirectorFeb 09Option Exercise26.6260,0001,596,900182,258Feb 13 05:24 PM
WILSON GAYLE EDirectorFeb 09Sale77.9260,0004,675,080122,258Feb 13 05:24 PM
MARTIN JOHN CExecutive ChairmanFeb 01Option Exercise23.6050,0001,180,0003,046,766Feb 05 08:38 PM
Alton Gregg HEVP,Corporate &Medical AffairsFeb 01Option Exercise40.5617,250699,66062,738Feb 05 09:20 PM
YOUNG KEVINChief Operating OfficerFeb 01Option Exercise0.00620015,547Feb 02 09:14 PM
Alton Gregg HEVP,Corporate &Medical AffairsFeb 01Sale83.5125,0002,087,86037,738Feb 05 09:20 PM
MARTIN JOHN CExecutive ChairmanFeb 01Sale83.5650,0004,177,8242,996,766Feb 05 08:38 PM
Meyers James REVP Worldwide Commercial OpsJan 16Option Exercise21.58100,0002,157,500102,715Jan 18 06:31 PM
Meyers James REVP Worldwide Commercial OpsJan 16Sale80.24100,0008,024,3642,715Jan 18 06:31 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJan 11Option Exercise36.0225,875932,06275,488Jan 16 05:42 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJan 11Sale79.0030,0002,370,00045,488Jan 16 05:42 PM
MARTIN JOHN CExecutive ChairmanJan 02Option Exercise23.6050,0001,180,0003,046,766Jan 04 07:54 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJan 02Option Exercise24.918,625214,80664,613Jan 04 08:05 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJan 02Sale73.8715,0001,108,01949,613Jan 04 08:05 PM
MARTIN JOHN CExecutive ChairmanJan 02Sale73.6250,0003,681,2352,996,766Jan 04 07:54 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffDec 01Option Exercise24.918,625214,80670,988Dec 05 06:17 PM
MARTIN JOHN CExecutive ChairmanDec 01Option Exercise21.5873,3331,582,1593,070,099Dec 05 07:49 PM
MARTIN JOHN CExecutive ChairmanDec 01Sale74.9873,3335,498,3852,996,766Dec 05 07:49 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffDec 01Sale74.6415,0001,119,55255,988Dec 05 06:17 PM
MILLIGAN JOHN FPresident and CEONov 13Option Exercise21.58220,0004,746,5001,385,924Nov 15 03:19 PM
MILLIGAN JOHN FPresident and CEONov 13Sale72.88220,00016,034,6781,165,924Nov 15 03:19 PM
Meyers James REVP Worldwide Commercial OpsNov 05Option Exercise0.004,50007,215Nov 07 05:47 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffNov 01Option Exercise24.918,625214,80677,363Nov 03 06:59 PM
MARTIN JOHN CExecutive ChairmanNov 01Option Exercise21.5873,3331,582,1593,070,099Nov 03 07:04 PM
MARTIN JOHN CExecutive ChairmanNov 01Sale75.1373,3335,509,6972,996,766Nov 03 07:04 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffNov 01Sale74.8215,0001,122,28562,363Nov 03 06:59 PM
MARTIN JOHN CExecutive ChairmanOct 02Option Exercise21.5873,3331,582,1593,070,099Oct 04 07:19 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffOct 02Option Exercise24.9117,250429,61193,738Oct 04 07:26 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffOct 02Sale82.6525,0002,066,30768,738Oct 04 07:26 PM
MARTIN JOHN CExecutive ChairmanOct 02Sale82.5673,3336,054,3192,996,766Oct 04 07:19 PM
Washington Robin LEVP, CFOSep 07Option Exercise24.3033,750819,95643,352Sep 11 08:35 PM
Washington Robin LEVP, CFOSep 07Sale85.0018,0701,535,950103,477Sep 11 08:35 PM
Washington Robin LEVP, CFOSep 07Sale85.0033,7502,868,7509,602Sep 11 08:35 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffSep 01Option Exercise24.9117,250429,611101,488Sep 06 06:56 PM
MARTIN JOHN CExecutive ChairmanSep 01Option Exercise21.5873,3331,582,1593,070,099Sep 06 08:23 PM
MARTIN JOHN CExecutive ChairmanSep 01Sale83.1173,3336,094,9922,996,766Sep 06 08:23 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffSep 01Sale83.0525,0002,076,18876,488Sep 06 06:56 PM
Meyers James REVP Worldwide Commercial OpsAug 31Option Exercise21.0060,0001,260,00062,715Sep 05 05:31 PM
Meyers James REVP Worldwide Commercial OpsAug 31Sale83.1960,0004,991,2902,715Sep 05 05:31 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffAug 30Option Exercise25.9243,1251,117,815134,238Sep 01 05:15 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffAug 30Sale79.0050,0003,950,00084,238Sep 01 05:15 PM
YOUNG KEVINChief Operating OfficerAug 10Option Exercise0.0091007,141Aug 14 06:57 PM
Meyers James REVP Worldwide Commercial OpsAug 10Option Exercise0.0082003,535Aug 14 06:53 PM
MARTIN JOHN CExecutive ChairmanAug 01Option Exercise21.5873,3331,582,1593,199,969Aug 03 06:55 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffAug 01Option Exercise26.998,625232,789106,113Aug 03 06:58 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffAug 01Sale75.8815,0001,138,19091,113Aug 03 06:58 PM
MARTIN JOHN CExecutive ChairmanAug 01Sale75.8673,3335,562,7773,126,636Aug 03 06:55 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJul 21Option Exercise26.9934,500931,155137,488Jul 25 06:53 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJul 21Sale74.0040,0002,960,00097,488Jul 25 06:53 PM
MARTIN JOHN CExecutive ChairmanJul 03Option Exercise21.5873,3331,582,1593,199,969Jul 06 06:38 PM
MARTIN JOHN CExecutive ChairmanJul 03Sale71.0073,3335,206,8923,126,636Jul 06 06:38 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJul 03Sale71.065,000355,295102,988Jul 06 06:27 PM
open in yahoo | open in reuters | open in google